Compare Stocks: AQST, HCM, GHRS, and TRLV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.25	$4.14	$2.93 ▼ $7.55	$533.42M	1.49	3.06 million shs	4.35 million shs
GHRS GH Research	$29.49	$26.25	$11.83 ▼ $31.44	$2.02B	1.29	331,731 shs	233,831 shs
HCM HUTCHMED	$12.20	$11.13	$9.77 ▼ $18.30	$2.13B	0.23	43,463 shs	13,090 shs
TRLV Trulieve Cannabis	$9.59 -0.6%	$8.93	$4.62 ▼ $13.28	$1.85B	N/A	786,242 shs	765,348 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+7.87%	+3.16%	+2.66%	+3.41%
GHRS GH Research	0.00%	-2.58%	+2.72%	+36.02%	+130.57%
HCM HUTCHMED	0.00%	-2.48%	+12.55%	+2.09%	-25.84%
TRLV Trulieve Cannabis	0.00%	+9.50%	+9.15%	+959,199,900.00%	+959,199,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.25	$4.14	$2.93 ▼ $7.55	$533.42M	1.49	3.06 million shs	4.35 million shs
GHRS GH Research	$29.49	$26.25	$11.83 ▼ $31.44	$2.02B	1.29	331,731 shs	233,831 shs
HCM HUTCHMED	$12.20	$11.13	$9.77 ▼ $18.30	$2.13B	0.23	43,463 shs	13,090 shs
TRLV Trulieve Cannabis	$9.59 -0.6%	$8.93	$4.62 ▼ $13.28	$1.85B	N/A	786,242 shs	765,348 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+7.87%	+3.16%	+2.66%	+3.41%
GHRS GH Research	0.00%	-2.58%	+2.72%	+36.02%	+130.57%
HCM HUTCHMED	0.00%	-2.48%	+12.55%	+2.09%	-25.84%
TRLV Trulieve Cannabis	0.00%	+9.50%	+9.15%	+959,199,900.00%	+959,199,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$8.50	100.00% Upside
GHRS GH Research	2.75	Moderate Buy	$45.00	52.59% Upside
HCM HUTCHMED	2.17	Hold	$14.87	21.86% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	56.38% Upside

Current Analyst Ratings Breakdown

Latest AQST, HCM, GHRS, and TRLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	GHRS GH Research	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$65.00
8/10/2026	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/7/2026	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $40.00
8/7/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00
8/6/2026	GHRS GH Research	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $39.00
7/31/2026	HCM HUTCHMED	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
7/27/2026	GHRS GH Research	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
7/27/2026	GHRS GH Research	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
7/23/2026	HCM HUTCHMED	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$16.00 ➝ $14.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.54M	11.98	N/A	N/A	($0.28) per share	-15.18
GHRS GH Research	N/A	N/A	N/A	N/A	$4.51 per share	N/A
HCM HUTCHMED	$548.51M	3.88	$2.69 per share	4.53	$7.17 per share	1.70
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
GHRS GH Research	-$48.26M	-$1.00	N/A	N/A	N/A	N/A	-20.07%	-19.41%	11/5/2026 (Estimated)
HCM HUTCHMED	$456.91M	N/A	N/A	55.45	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	22.31	N/A	N/A	N/A	N/A	N/A

Latest AQST, HCM, GHRS, and TRLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	GHRS GH Research	-$0.2860	-$0.23	+$0.0560	-$0.23	N/A	N/A
7/30/2026	H1 2026	HCM HUTCHMED	$0.1450	$0.05	-$0.0950	$0.05	$304.16 million	$139.14 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
GHRS GH Research	N/A	28.70	28.70
HCM HUTCHMED	0.06	5.64	5.50
TRLV Trulieve Cannabis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
GHRS GH Research	56.90%
HCM HUTCHMED	8.82%
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
GHRS GH Research	N/A
HCM HUTCHMED	3.60%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	125.51 million	116.97 million	Optionable
GHRS GH Research	10	68.61 million	N/A	Optionable
HCM HUTCHMED	1,796	174.47 million	168.19 million	Not Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	N/A

AQST, HCM, GHRS, and TRLV Headlines

Recent News About These Companies

Trulieve Cannabis (NYSE:TRLV) Trading Up 8.3% - Here's What Happened

August 13, 2026 | marketbeat.com

3 Marijuana Stocks For Investors To Consider

August 12, 2026 | marijuanastocks.comM

Trulieve Completes Redomicile from British Columbia to Delaware

August 11, 2026 | prnewswire.com

Trulieve Cannabis' (TRLV) Overweight Rating Reiterated at Cantor Fitzgerald

August 10, 2026 | americanbankingnews.com

Trulieve Cannabis Q2 Earnings Call Highlights

August 9, 2026 | marketbeat.com

Trulieve Cannabis (TRLV) Reports Steeper Losses And Lower Sales, Is The Valuation Discount Justified?

August 8, 2026 | uk.finance.yahoo.com

Trulieve Cannabis (NYSE:TRLV) Rating Lowered to "Hold" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Trulieve Cannabis (NYSE:TRLV) Cut to Hold at Wall Street Zen

August 8, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Releases Earnings Results, Beats Estimates By $0.05 EPS

August 7, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Update: Key Signals to Watch

August 7, 2026 | kalkinemedia.comK

Trulieve Cannabis Corp. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Trulieve Cannabis (NYSE:TRLV) Given Overweight Rating at Cantor Fitzgerald

August 7, 2026 | marketbeat.com

Trulieve: Q2 Earnings Snapshot

August 7, 2026 | chron.com

Trulieve Reports Second Quarter 2026 Results

August 7, 2026 | prnewswire.com

Der aktuelle Kurs der Trulieve Cannabis Corp Aktie beträgt 8,9600.

August 5, 2026 | de.investing.com

Trulieve Announces August 2026 Event Participation

August 5, 2026 | prnewswire.com

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Large Growth in Short Interest

July 28, 2026 | marketbeat.com

Cantor Fitzgerald Begins Coverage on Trulieve Cannabis (NYSE:TRLV)

July 20, 2026 | marketbeat.com

Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida

July 16, 2026 | prnewswire.com

Why Is Trulieve (NYSE:TRLV) Expanding Its NYSE Presence?

July 13, 2026 | kalkinemedia.comK

Two marijuana MSOs named among ‘America’s Best Companies’

July 10, 2026 | mjbizdaily.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, HCM, GHRS, and TRLV Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.25 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.22 -0.03 (-0.59%)

As of 08/14/2026 07:39 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

GH Research NASDAQ:GHRS

$29.49 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$29.82 +0.33 (+1.10%)

As of 08/14/2026 07:38 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

HUTCHMED NASDAQ:HCM

$12.20 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$12.21 +0.01 (+0.08%)

As of 08/14/2026 07:34 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Trulieve Cannabis NYSE:TRLV

$9.59 -0.06 (-0.60%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$9.64 +0.04 (+0.45%)

As of 08/14/2026 07:45 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, HCM, GHRS, and TRLV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, HCM, GHRS, and TRLV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, HCM, GHRS, and TRLV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, HCM, GHRS, and TRLV Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

GH Research NASDAQ:GHRS

HUTCHMED NASDAQ:HCM

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, HCM, GHRS, and TRLV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, HCM, GHRS, and TRLV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, HCM, GHRS, and TRLV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, HCM, GHRS, and TRLV Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

GH Research NASDAQ:GHRS

HUTCHMED NASDAQ:HCM

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools